OncoMyx has built an immunotherapy platform that uses myxoma, a natural oncolytic virus, to deliver multiple cancer-killing payloads in a single therapeutic. The myxoma platform is engineerable as a large dsDNA poxvirus, inherently immuno-interactive, not pathogenic to humans, and amenable to IV and repeat dosing. Its multi-armed myxoma virus expresses different antitumor immunomodulatory proteins to modulate the tumor microenvironment and stimulate anti-tumor immunity. The company has generated preclinical safety and efficacy data across a broad range of models and plans to advance its lead candidate into clinical trials next year to assess IV dosing safety and efficacy. OncoMyx’s platform was developed from research in Dr. Grant McFadden’s lab and was exclusively licensed from Arizona State University. The company emphasizes combination potential with checkpoint inhibitors and chemotherapies and has assembled an experienced immuno-oncology team to advance its pipeline. OncoMyx Therapeutics develops oncolytic immunotherapies using a proprietary myxoma virus (MYXV) platform. The MYXV platform was spun out from Arizona State University and is supported by over 30 peer-reviewed publications by ASU Professor Grant McFadden and collaborators. Preclinical studies in mice and testing on cancer patient samples from the Mayo Clinic in Scottsdale have shown encouraging immune responses against tumors. The company positions its MYXV approach as non-human-pathogen, inherently immuno-stimulatory, easily multi-armed, and amenable to systemic delivery to complement immune checkpoint blockade. OncoMyx plans to use its recent financing to advance development of its lead oncolytic virus therapeutic program for the treatment of various cancers. The company has assembled a team of OV experts including founder/CEO Steve Potts and research advisor Grant McFadden.

Total raised

$75M

Funding rounds

2

Latest round

Series B

Latest activity

Dec 2021